An artificial intelligence-generated R.E.N.A.L.+ score — developed by a team of researchers at Cleveland Clinic — proves superior to the traditional scoring system for the prediction of renal oncologic outcomes.
Researchers aim to develop a new type of cancer therapy that actually repairs diseased cells rather than simply destroying them.
A new guideline from the American Urological Association provides clinicians with advice on best practices for managing patients with localized renal masses and cancers.
The key is semantic segmentation of kidneys and kidney tumors — linking each pixel in a CT scan to a specific label — and training a computer to recognize the images, in a method known as deep learning.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Partial nephrectomy has demonstrated positive outcomes over the last decade, becoming the preferred surgical approach for treating renal cancer. But some experts say this may have more to do with selection bias. More clinical studies are needed to better characterize partial nephrectomy versus radical nephrectomy.
It was a classic case of an incidental finding on CT. A scan for appendicitis revealed two renal neoplasms in a 12-year-old. Urologists, geneticists, radiologists and the family team up to determine the best course.
Two multisite clinical trials of advanced renal cell carcinoma (RCC) treatments recently reported encouraging results for the 30 percent of RCC patients worldwide with advanced-stage or metastatic disease and historically poor prognosis.
This randomized phase 3 study compared treatment with sunitibib with a combination therapy of the anti-VEGF drug bevacizumab and atezolizumab, an engineered monoclonal antibody against PD-L1.
Accurate renal function measurement is critical to predict long-term adverse outcomes after nephrectomy. The relationship between chronic kidney disease and poor clinical outcomes is robust, but prediction can be improved by incorporating proteinuria.
Early data from renal cancer dual drug trial reinforces cancer field’s optimism for immunotherapy approaches.